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Summary Electrochemotherapy (ECT) is a new therapeutic approach combining the effects of a low-permeant cytotoxic drug, bleomycin
(BLM), administered i.v. and cell-permeabilizing electric pulses (EPs) locally delivered to tumours. The transient permeabilization of the cell
membrane by the EPs allows free access of BLM to its intracellular targets, largely enhancing BLM's cytotoxic effects. ECTefficacy has been
proved so far on transplanted subcutaneous murine tumours and on subcutaneous metastases in humans. Here, we present the firststudy of
the effects of ECT on tumours transplanted to livers in rabbits. We used a recently developed EP applicator consisting of an array of parallel
and equidistant needles to be inserted in tissues. Effects of EPs alone or of ECT were assessed by histological analysis, tumourgrowth rates
and survival of the treated animals. A transient blood hypoperfusion was seen in the electropulsed areas, with or without BLM, related to EP-
dependent vasoconstriction but this had no major effects on cell survival. Long-term effects depended on the presence of BLM at the time of
EP delivery. Almost complete tumour necrosis was observed after ECT, resulting from both BLM direct cytotoxic effects on electro-
permeabilized tumour cells and indirect effects on the tumourvessels. A large reduction in tumourgrowth rate and significantly longer survival
times were scored in comparison with control rabbits. Moreover, ECT of liver tumours was well tolerated and devoid of systemic side-effects.
When ECT was associated with a local interleukin 2-based immunotherapy, increased local anti-tumour effectiveness as well as a large
decrease in the number of metastases were observed. Thus, ECT could become a novel treatment modality for liver tumours and other solid
internal malignancies.
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Bleomycin (BLM), a non-permeant cytotoxic drug largely used in
clinical oncology (Sikic, 1988; Mir et al, 1996), is a relatively
large hydrophilic molecule that is carried into the cells by a low-
efficiency mechanism (Pron et al, 1994). Consequently, very small
amounts of BLM enter intact cells, limiting its cytotoxic effects
(Orlowski et al, 1988; Poddevin et al, 1991). Brief and intense
electric pulses (EPs) delivered in vitro or in vivo are known to
induce changes in the plasma membrane of the pulsed cells,
resulting in a transient and reversible cell permeabilization (Chang
et al, 1992; Orlowski and Mir, 1993). One of the most innovative
and promising biomedical applications ofelectropermeabilization
is the therapeutic use of this technique to incorporate cytotoxic
drugs into tumour cells (Mir et al, 1995a). In vitro cell electroper-
meabilization enhances BLM influx into electropulsed cells and
thus greatly potentiates BLM cytotoxicity (Orlowski et al, 1988;
Poddevin et al, 1991). Furthermore, in vivo experiments on
tumour-bearing mice demonstrated that BLM potent anti-tumour
effects were obtained by delivering transcutaneous EPs to subcuta-
neous tumours by means of external electrodes (Mir et al, 1991).
The effectiveness of this approach has been proved on a large
variety ofmurine subcutaneous tumours (Belehradek J et al, 1991;
Sersa et al, 1994; Heller et al, 1995) and on spontaneous soft tissue
sarcomas in cats (Mir et al, 1997). The usefulness ofthis method in
deeply located tumours has also been reported on brain-implanted
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gliomas in rats using two needles stereotaxically inserted at each
side of the tumour (Salford et al, 1993). We have termed this new
therapeutic principle, which combines the systemic administration
of BLM with local permeabilizing EPs, electrochemotherapy
(ECT) (Mir et al, 1991, 1995a). ECT provokes a transient local
peritumoral oedema followed by the rapid disappearance of the
treated tumour. We have previously shown the role of the host's
immunological response in achieving cures induced by ECT in
murine tumour models (Mir et al, 1992). Moreover, the combina-
tion of ECT with an interleukin 2 (IL-2)-based immunotherapy,
used to stimulate the host's immune system, led to increased local
anti-tumour effects and, even more important, revealed systemic
anti-tumour effects (Mir et al, 1995b).
Clinical use ofECT alone has already shown good tolerance and
response rates on subcutaneous permeation nodules of heavily
pretreated patients with head and neck squamous carcinoma
(Belehradek M et al, 1993; Domenge et al, 1996), as well as on
cutaneous or subcutaneous metastatic melanomas and on basal cell
carcinomas (Heller et al, 1996; Mir et al, 1998). To apply this ther-
apeutic strategy to other malignancies, such as visceral tumours, it
appeared necessary to investigate the functional and histological
effects of ECT on an experimental model of internal tumour.
Factors such as the absence ofthe skin barrier could have an influ-
ence on the ECT application conditions or effects. In particular, our
basic studies on tissue electropermeabilization demonstrated the
importance of the geometry of the field lines, obviously related to
the electrodes used (Belehradek J et al, 1994).
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To approach simultaneously the treatment of internal deep
tumours and oflarge and thick tumour nodules, for which mice are
not suitable, we treated VX2 tumours transplanted in the livers of
rabbits (Miller et al, 1987). We used a recently developed device
for EP delivery that consists in parallel and equidistant needle
electrodes forming a centred hexagonal array (Mir et al, 1997). On
insertion in the tissues, this needle configuration divides the
overall tumour volume in small unit volumes. Thus, even in the
case oflarge tumours, ECT will not require too high voltages to be
delivered between each pair of neighbouring needle electrodes as
the voltage necessary to obtain cell permeabilization is propor-
tional to the distance separating the electrodes. Moreover, the
needles allow the deepest parts ofthick tumours to be reached. The
aim ofour work in rabbits was to determine the ECT effectiveness
on experimental liver tumours. We report here that (a) a transient
blood hypoperfusion was seen on the electropulsed areas, with or
without BLM; (b) in the presence of BLM, almost complete
tumour cell death was observed, due to a combination of direct
BLM cytotoxicity and indirect vascular effects; (c) ECT caused a
clear reduction in the tumour growth rate, significantly increased
survival times as well as cure achievement; (d) when an IL-2-
based immunotherapy was associated with ECT, the local anti-
tumour effectiveness was increased and the number of metastases
was largely decreased.
MATERIALS AND METHODS
Animals and tumours
New Zealand white rabbits (Elevage Scientifique des Dombes,
Romans, France) were maintained under standard conditions with
a laboratory diet and water ad libitum. All procedures were carried
out under general i.v. anaesthesia using ketamine hydrochloride
(Ketamine, Parke Davis, Courbevoie, France) and xylazine 2%
(Rompun, Bayer, Puteaux, France). The experiments were
conducted in accordance with European Council directives and
French legislation concerning animal welfare. The VX2 carcinoma
was maintained by serial passages in the liver in carrier rabbits, as
previously described (Munck et al, 1993). Hepatic implantation of
VX2 carcinoma cells was accomplished through a small median
subxyphoid incision. A tumour was removed from one animal,
minced in NCTC 109 medium (Eurobio, Paris, France) and filtered
through cotton gauze. Samples of I07 VX2 cells in 100gl of
medium were injected with a 30-gauge needle under the hepatic
capsule, resulting in the development ofa localized hepatic tumour
2 weeks later (diameter 6-18 mm). To comply with the major
constraint of the last series of experiments (generation of single
tumours, in the absence of other small tumour nodules growing
beside the main tumour due to tumorigeneic cell spreading at the
time of VX2 cell inoculation) small tumour fragments of 2-4 mm3
were transplanted under the hepatic capsule. Two weeks later, these
tumours reached diameters between 6 and 11 mm.
Therapeutical procedures
Electrochemotherapy
The rabbits were anaesthetized and a subxyphoid incision was
performed to expose liver tumours. Bleomycin (Laboratoire Roger
Bellon, Neuilly-sur-Seine, France) dissolved in sterile 0.9% sodium
chloride, was injected as a bolus i.v. dose of 0.5 or
I mg kg-'. This dose is not the maximum tolerated dose of BLM
but the dose used in previous preclinical trials in mice and in cats
(Mir et al, 1992, 1995b, 1997), and similar to that used in clinical
trials (Belehradek M et al, 1993; Domenge et al, 1996). The electric
component of the treatment by ECT consisted of eight square-
waved EPs of 100 ts length delivered between 4 and 12 min after
the end of the BLM infusion. In accordance with previous ex vivo
studies that determined the permeabilizing threshold for tumour
tissues (Belehradek J et al, 1994), the electric field intensity applied
was 850 V cm-'. The electric signal delivered was checked through
a digital storage oscilloscope (Hitachi, Tokyo, Japan). Two genera-
tors delivering the same type of EPs were used for the EP delivery
(a) a Jouan PS15 electropulsator (Nantes, France) connected to two
stainless-steel plates or to two acupuncture needles fixed 6 mm
apart and held by an insulating template, delivering the run ofeight
square pulses at the frequency of I Hz; the metal plate electrodes
were placed on the surface of the abdominal organs, whereas the
needle electrodes were positioned and inserted into the normal
tissues and the tumours; after each run, the needle electrodes
assembly was repositioned into the tumour along different direc-
tions (mean = 11 runs) to ensure coverage of the whole tumour
volume; (b) a CELTEM MKO generator (Antony, France)
connected to an electrode assembly consisting of seven equidistant
and parallel needles (5 cm length) arranged in a centred hexagonal
array, defining 12 electrode pairs separated by 6 mm; for each run,
the square pulses, delivered by the generator at a frequency of8 Hz,
were distributed successively to each electrode pair by an inte-
grated switch in order to deliver eight pulses (four ofeach polarity)
between every pair of needles at a final frequency of0.67 Hz, with
a total duration of 12 s for the entire run; after each run, the needle
electrode assembly was repositioned into the tumour to ensure
coverage ofthe whole tumour volume by the application ofsix runs
(Mir et al, 1997). All the tumour treatments were performed with
needles. The same effects were observed with either the two- or the
seven-needle devices, provided that the coverage of the whole
tumour volume was ensured by multiple positioning ofthe needles
within the tumour. Obviously, the seven-needle device was more
convenient, particularly for the treatment ofthe largest tumours.
Immunotherapy
IL-2 gene-transfected Chinese hamster CHO(IL-2) cells (Ferrara
et al, 1987) were routinely maintained in vitro in MEM culture
medium supplemented with 8% fetal calf serum and antibiotics. In
vitro they secrete 3500 IL-2 units of the Biological Response
Modifiers Program per millilitre, 72 h and 0.8 x 105 initially
seeded cells. For rabbit treatment, 30 x 106 CHO(IL-2) cells,
resuspended in 200-300 ,ul of MEM without serum, were injected
intratumorally, either in the absence of any other treatment or in
combination with ECT, within 10 min after the delivery of the EP
to the tumours.
Controls
Control rabbits, without treatment, were laparotomized 2 weeks
after VX2 tumour implantation and their tumours measured. After
surgery, they were maintained and followed up like treated animals.
Other control groups included rabbits receiving either (a) only EPs,
or (b) only BLM, or (c) only injection ofCHO(IL-2) cells.
Effects on normal tissues
The effects ofECT were studied in vivo during EP application, and
subsequently by sequential histological analysis. The peroperative
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Figure 1 Histological observations of VX2 tumours after ECT. ECT
consisted of square-waved EPs of 850 V cm-' electric field intensity and of
100 ,s length, applied using the PS15 electropulsator from 4 min after the
BLM i.v. (0.5 mg kg-') injection onwards. (A) At day 2 after ECT. Tumour
necrosis with isolated cell nuclei, associated with inflammatory cell infiltration
around the necrosed area. Scale bar, 100gm. (B) At day 9 after ECT.
Tumour necrosis associating fibrotic reaction, and marked vascular lesions
with endothelium alterations and intraluminal thrombus. Scale bar, 200 ,um.
(C) At day 30 after ECT. Massive tumour necrosis with total disappearance of
tissue organization. Scale bar, 500,m
vascular effects were assessed by the distribution of fluorescein
either before or after the EP delivery. EPs, alone or in combination
with BLM, were applied on the left lobe ofthe liver ofhealthy (non-
tumour-implanted) rabbits and immediately after this treatment, the
dye was injected i.v. (0.02 mg in 1 ml) and the livers illuminated
with a Woods light. The same experiment was performed on control
rabbits without treatment, and in both cases staining of the livers
was observed.
Histological analysis oftissues was performed on rabbits killed
10 min and 1 h later, to study early alterations, especially vascular
lesions. Late changes in normal tissues were also assessed by
macroscopic and microscopic analysis of samples of livers,
kidneys, pancreas and spleens obtained 2 days after the treatment.
Samples were fixed in Bouin's fixative. Paraffin-embedded
sections were stained with haemalun-eosin.
Anti-tumour efficacy and survival
The evolutive changes in tumour response were analysedby histo-
logical examinations up to 30 days after treatment. Short-term
anti-tumour efficacy of ECT was tested by comparing the tumour
growth rates in four groups of rabbits. The VX2 tumour is a
rapidly growing and aggressive carcinoma, and consequently the
evaluation end point for the anti-tumour effects was fixed at 9 days
after the treatment. Each experimental group was composed of six
rabbits receiving either (a) no treatment or (b) i.v. BLM alone or
(c) EPs alone or (d) ECT. Tumour volumes (V) on the treatment
day were measured through a subxyphoid incision using calipers
to determine the three largest perpendicular diameters a, b and c,
and then applying the formula: V = rtabc/6. All tumours were
measured at the treatment time and 9 days later when the rabbits
were killed. The tumour growth rate for each animal was estab-
lished from the ratio ofthe tumour volumes at day 9 to those at day
0 by [(Vd9/Vdo) -1] x 100. In the four experimental groups, histo-
logical confirmation of tumour response and the determination of
the percentage of tumour necrosis were performed by two inde-
pendent observers. To accurately estimate the anti-tumour effects
ofECT, a tumour growth score was established taking into account
the former tumour growth rate corrected by the estimated necrosis
rate ofeach individual tumour at day 9.
In survival experiments, the local response of the implanted
tumour as well as the number and the location of metastases were
determined at the time of the rabbit's death. To perform necropsy
under good conditions immediately after death, animals were
killed when their general status was very low, which was estimated
from a daily follow-up consisting in weight determination and in
behaviour observation.
Anti-tumour effects were statistically compared using the non-
parametric Mann-Whitney test for tumourgrowth rates (Figure 2),
and the Mantel-Haenzel log-rank test for survival times
(Figure 3). Statistical comparisons in Tables 1 and 2 were made
using contingency tables analysis and exact X2 Fischer's test.
Significance was assumed for tests at P < 0.05.
RESULTS
Effects of bleomycin alone
BLM alone, at the doses used (0.5 mg kg-'), did not induce any
histological change in healthy tissues compared with the controls.
Tumours treated by i.v. BLM alone at the same dose showed histo-
logical aspects indistinguishable from native non treated tumours.
In both cases, necrotic areas reached approximately 10% of the
tumour volume 9 days after the treatment. These results could be
expected as the BLM doses used were far below the maximum
tolerated dose.
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Figure 2 Tumour growth rates and tumour growth scores determined 9
days after the treatments. At the time of the treatment, tumour volumes were
determined as described in Materials and methods. Experimental groups: 1,
ECT; 2, EPs alone; 3, BLM i.v. (1 mg kg-') alone; 4, untreated controls. ECT
consisted of square-waved EPs of 850 V cm-1 electric field intensity and of
100 ps length, applied using the MKO electropulsator from 4 min after the
BLM i.v. (1 mg kg-') injection onwards. Nine days later, rabbits (six in each
group) were killed. Tumours were removed, measured and processed for
histological determinations of the necrosis percentage. (A) Relative tumour
volume increases according to the ratio of the macroscopically measurable
volume at day 9 to the macroscopically measurable volume at the day of the
treatment. The value of the ECT group is statistically different (P < 0.05) from
the values of the three other groups. (B) Relative increases when tumour
volumes at day 9 are corrected by the histologically determined percentage
of necrosis. The value of the ECT group is statistically different (P < 0.02)
from the values of the three other groups
Table 1 Survival experiments using rabbits with VX2 carcinoma in the liver
generated by tumour fragment transplantations
Treatment Per cent of Median survival
cured rabbits (days)
None 0 50
Electric pulses 0 51
IL-2-secreting cells 0 45
ECT 30 82
ECT and IL-2-secreting cells 40 80
Long-term survivors and median survival times were determined in groups of
five rabbits, except in the ECT group, which consisted of ten rabbits. ECT
was performed as in Figure 2. Rabbits were considered to be cured if they
survival more than 250 days after treatment without any sign of disease.
Effects of electric pulses alone
In tissues submitted to EPs alone, immediate reactions were
observed as colour modifications restricted to the electropulsed
areas. On the spleen, we noticed an immediate reduction in the
volume of the pulsed area. When EPs were applied on the
pancreas, mesenteric vessel branches showed a reduction of their
vascular diameter, with perivascular oedema. After EP application
to the liver, fluorescein was injected and illumination with a
Woods light revealed no dye coloration of the pulsed volume,
confirming the absence of blood flow. In all cases, blood flow
breakdown was observed transiently, over 15-20 min. After this
time, tissues progressively recovered their initial colour and
consistence, and no bleeding was ultimately observed at the needle
insertion sites. It is noteworthy that the application of EPs on
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Figure 3 Survival curves of rabbits with VX2 carcinoma in the liver
generated by the injection of tumour cell suspensions. The nine control
rabbits (0) had VX2 carcinoma but received no treatment. The eight treated
rabbits (0) received ECT 2 weeks after VX2 cell injection in the liver. ECT
was performed as in Figure 2 and rabbit survival (in days after tumour cell
inoculation) was checked daily. The difference between the two curves is
statistically significant according to the log-rank test, with P < 0.02
normal tissues and tumours did not induce distant side-effects and
was fairly well tolerated locally.
The immediate histological analysis (10 min and 1 h after appli-
cation ofEPs) showed markedly congestive tissues and interstitial
oedema. The presence of fibrin deposits between the vascular
layers as well as the loose perivascular oedema observed on
mesenteric vessels confirmed an enhanced vascular permeability.
No evidence of cell damage or change in tissue organization was
observed except a sparsely distributed endothelial damage on
pulsed areas: arteries were distorted, showing thrombus and
perivascular oedema with an eosinophil inflammatory infiltrate.
Two days after EP delivery, the liver, pancreas, kidney and
spleen showed minor local necrosis and vascular damage. These
lesions were focal, limited to the electrode contact sites, and treat-
ment did not induce diffuse organ damage or distant side-effects.
At day 9 after EPs alone, percentages of necrosis in the pulsed
tumours were estimated from 10% to 20-25%, depending on the
number of EP runs. These should be compared with the sponta-
neous necrosis of untreated tumours, which was 10-15%. Lesions
were sparsely distributed with minimal vasculardamage, and local
necrosis and fibrosis were seen just at the electrode application
site. EP delivery did not induce diffuse organ damage or distant
side effects.
Effects of electrochemotherapy
Histological analyses
In the presence of BLM, the early vascular effects ofEPs detected
in the absence of BLM were also present, without histological
differences, and the macroscopic aspects ofeach treated area were
also indistinguishable. However, the treatment by ECT or EPs
alone induced quite different evolutive changes with characteristic
histological patterns.
Two days after ECT, examination of the tumours revealed
severe lesions consisting in a polygonal necrotic lesion corre-
sponding to the geometry of the liver area crossed by permeabi-
lizing electric field intensities. Dead cells were surrounded by an
eosinophil inflammatory infiltrate, and the structures of pulsed
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Table 2 Local and systemic tumour progression at the death of rabbits with VX2 carcinoma in livers generated by tumour fragment transplantations
Treatment Per cent of rabbits with Average number of Per cent of rabbits with
local regression of the countable metastases massive lung
treated tumour invasion by
micrometastases
None 0 27 60
Electric pulses 0 16 60
IL-2-secreting cells 0 58 0
ECT 50 18 50
ECT and IL-2-secreting cells 80 3 0
Local progression of liver tumours and the presence of metastases at necropsy were determined in groups of five rabbits, except in the ECT group,
which consisted of ten rabbits. ECT was performed as in Figure 2. Local tumour response corresponded to the absence of live tumour tissue at the
site of the treated tumour. For evaluation of the metastatic dissemination, we distinguished, on one hand, the well-limited and macroscopically
countable secondary tumour nodules on the various organs inspected during the necropsy and, on the other hand, the massive lung infiltration by
micrometastases.
tissues were distorted, showing isolated nuclei and considerable
vascular damage (Figure IA). Nine days after ECT, we observed
a massive necrotic area, with 100% necrosis in some cases,
surrounded by fibrosis. Arteries were severely damaged showing
an endothelium detached from the basal membrane, with intra-
mural fibrin clotting and thrombosis (Figure IB). Thirty days after
ECT, total disappearance of tissue structures was observed and a
hyaline reaction on infarction areas, with no viable tumour
residues (Figure IC). Lesions after ECT and EPs alone were thus
quantitatively and qualitatively different. However, application of
ECT did not provoke distant side-effects.
Effects on tumourgrowth
ECT clearly reduced the liver tumour growth rates when compared
with treatments by EPs alone, i.v. BLM alone (1 mg kg-'), or to
absolute controls without any treatment (Figure 2). The precise
measurement of tumour limits after treatments was made difficult
because the normal liver tissue surrounding the tumour, which was
also electropermeabilized, showed an intense fibrosis. Thus, ECT
efficacy was probably underestimated by these macroscopic
measurements of apparent tumour volume. Nevertheless, tumour
growth rates determined at day 9 showed significant differences
between the ECT group (relative tumour volume increase 280%)
and any other group (relative tumour volume increases in the range
790-890%) (Figure 2A). After histological assessment of the
tumour responses in terms of percentage of cell necrosis, the
tumour growth score was determined as it better reflected the
short-term effects of ECT. The differences in the tumour growth
scores were much greater, with a net decrease ofthe viable tumour
volume after ECT (Figure 2B).
Survival experiments
When compared with the control non-treated animals (mean
survival of 38 ± 4 days after tumour cell inoculation), a significant
increase in lifespan of the animals treated by ECT was obtained
(mean survival of 60 ± 7 days) (Figure 3). However, no cure was
obtained. We wondered whether cure absence was related to the
initial procedure for tumour transplantation based on tumour cell
injections under the hepatic capsule. Indeed, the generation of a
liver tumour by this procedure could induce, besides the larger
tumour treated by ECT, small nodules. These nodules could be due
to cell spreading from the inoculation site at the time of cell injec-
tion and would not be detectable at the treatment time.
Thus, to obtain a unique well-defined tumour at the treatment
time, we repeated the experiments with a modified protocol for
tumour transplantation using small VX2 tumour fragments grafted
into the left lobe of rabbit livers. Delivery of EPs alone did not
modify the median survival time compared with the non-treated
rabbits (treatment by BLM alone was not performed as we have
already extensively documented that BLM, at the doses used for
ECT, never modifies tumour evolution). All the animals in these
two groups died before 98 days after treatment, with a median
survival time ofabout 50 days. In contrast, in the ECT group, three
out of ten rabbits survived for more than 250 days and were
considered as cured, and the whole group had a median survival
time of 82 days (Table 1).
To quantify more precisely the long-term local and systemic
anti-tumour effects ofthe treatments, we systematically performed
necropsy after the rabbits died. The two control groups, no treat-
ment or EP alone, never showed local regression of the primary
liver tumour (Table 2). Furthermore, they displayed a large
number of visceral metastases and a high frequency of massive
lung metastatic spreading (Table 2). After treatment with ECT,
50% of the rabbits showed a local regression of the primary liver
tumour, but the numberofvisceral metastases and the frequency of
massive lung invasion were similar to that of the two control
groups (Table 2). The difference in the number oflocal regressions
in the ECT-treated group (ten rabbits) vs the absolute control and
the EPs alone control (5 + 5 rabbits that had exactly the same
behaviour) is statistically significant (P < 0.05).
Effects of electrochemotherapy combined with
immunotherapy
The anti-tumour effects of the combination of ECT with an IL-2-
based immunotherapy was assayed by performing two other
experimental groups: (a) the local administration of histoincom-
patible IL-2 secreting cells alone; and (b) the combination of ECT
with the administration of these cells. The control group receiving
the immunotherapy alone showed a median survival time similar
to that ofthe two other control groups (no treatment or EPs alone)
(Table 1). However, two rabbits of the immunotherapy alone
control group displayed a very long survival time (131 and 236
days) due to slow tumour evolution. When combined with ECT,
the immunotherapy increased neither the percentage of long-term
survivors nor the median survival time observed with ECT alone.
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Therefore, the administration of these cells, alone or combined,
did not result in modifications of animal survival. Taken together,
the rabbits treated by ECT on the one hand (10 + 5 rabbits) and the
rabbits not treated by ECT (5 + 5 + 5 rabbits) on the otherhand, the
difference in the number of cures obtained, attributable to the ECT,
is statistically significant (P < 0.05).
The rabbits treated by the IL-2-secreting cells alone showed no
local regression of the primary liver tumour and an increased
number of visceral metastases (Table 2). However, no massive
lung metastatic spread was observed (Table 2). In fact, this group
was heterogeneous: three rabbits had short survival times and
exhibited a very large number of metastases, one rabbit had a
moderately increased survival time and a tumour mass resulting
from the confluence of a large number of peritoneal metastases,
and one rabbit had a very long survival related to the slow growth
of the transplanted tumour. This rabbit showed a few small metas-
tases, and the non-implanted lobes of the liver were still free of
tumour at the necropsy. In the case ofcombination ofECT with the
IL-2-based immunotherapy, not only was the frequency of local
regression of the primary liver tumour increased, but the number
of visceral metastases was largely decreased, and no rabbit
displayed a massive metastatic spreading in the lungs (Table 2).
The difference in the number of local regressions in the ECT
plus immunotherapy-treated group (five rabbits) vs its strict
control, i.e. the immunotherapy alone-treated group (five rabbits),
is statistically significant (P < 0.05) as in the comparison between
ECT alone and its strict controls (see above). Finally, the differ-
ence in the number of local regressions in the ECT-treated animals
(10 + 5 rabbits) and in the rabbits not treated by ECT (5 + 5 + 5
rabbits) is highly statistically significant (P < 0.001).
There is a large difference in the average number of visceral
metastases between, on the one hand, the absolute control, the EP
alone and the ECT groups, and, on the other hand, the group
treated by the combination of ECT and immunotherapy. However,
the statistical comparison is hampered by the large dispersion in
the number of metastases in each experimental group. Moreover,
each experimental group consisted of a limited number ofanimals
because of the constraints inherent to this experimental model,
both in the treatment and in the follow-up of the rabbits.
DISCUSSION
Safety of the EP application using needle electrodes
The application of EPs alone on normal tissues or on tumours
appears to be safe. Only a transient local hypoperfusion of the
electropulsed area was observed, followed by blood flow recovery
several minutes later. No distant effects of the EPs were detected
beyond the treated sites, except the reduction in the diameter of
mesenteric vessel branches and a slight oedema after EP delivery
to the pancreas. This good tolerance probably results from the
virtual absence of thermal effects because of the extremely short
duration of the EPs delivered. The applied electric currents could
induce local pH changes, but any in vivo influence ofthis effect is
limited to the contact surface of the electrodes. The absence of
bleeding even with the use ofneedles deeply inserted several times
into the liver parenchyma is another aspect of the safety of EP
delivery. This absence could be due to the transient local hypoper-
fusion as well as to a type ofelectrocoagulation at the needle inser-
tion point related to the very high current density at the surface of
the needle electrodes. This electrocoagulation would be consistent
with the observation that the treatment of tumours by EPs alone
does not induce an increase in the metastatic dissemination of
tumour cells (Table 2), as could be feared with the insertion of
'passive' needles into tumours.
Direct bleomycin cytotoxic effects
In this study, we confirm that ECT can be extended to the treat-
ment of internal tumours including those located in visceral
organs. Moreover, increase in rabbit survival and even cures were
obtained. However, in the initial tumour inoculation procedure
(the inoculation oftumour cells under the hepatic capsule, prone to
produce tumour cell spreading at the time of tumour transplan-
tion), ECT did not result in long-term survivors. When tumours
were prepared by transplantation of small tumour fragments (a
procedure supposed to be almost free of tumour cell detrimental
dissemination at the time oftumour transplantation), ECT resulted
in obtaining 50% (five out of ten) of local complete responses and
30% (three out often) disease-free long-term survivors. Therefore,
as previously shown in other preclinical models (Belehradek J et
al, 1991; Mir et al, 1991, 1997; Salford et al, 1993), ECT is an effi-
cient local treatment. Moreover, the ECT-treated rabbits exhibited
a very good general tolerance.
As previously demonstrated in vitro on cell suspensions and in
vivo on murine tumours, the basal mechanism of ECT efficacy is
BLM electroloading into tumour cells (Poddevin et al, 1991;
Belehradek J et al, 1994). On one hand, tumour cell permeabiliza-
tion induces high cytotoxicity only when BLM is present, which
means that ECT efficacy depends on the presence of BLM within
the whole electropulsed tumour volume. This is clearly illustrated
in Figure 2. The fact that a very limited number ofBLM molecules
internalized in the cytosol is sufficient to induce cell death indi-
cates that moderate non-toxic BLM i.v. doses should be sufficient.
As a matter of fact, in the reported experiments, BLM i.v. doses
were far below the maximum tolerated dose. On the other hand,
BLM induces high anti-tumour effects only when tumour cells are
permeabilized. The fact that massive tumour cell death was
observed as early as 48 h after ECT (in agreement with previous in
vitro cell death studies by Tounekti et al, 1993) and the extent of
the residual fibrosis of the ECT-treated tumours show that the
intratumoral application of EPs by the needle electrodes used is
efficient in permeabilizing the tumour cells. However, we previ-
ously reported ex vivo experiments showing that a fraction of the
cell content of an electropulsed tumour fragment is not electroper-
meabilized. The large decrease observed in tumour growth rates
after ECT, as compared with EPs alone or BLM alone, indicates
the implication of additional anti-tumour mechanisms, such as
vascular effects and immunological effects.
Vascular effects
In this study we observed new effects of EPs on living tissues and
we distinguished early and late vascular effects of EPs, which are
probably related to different physiopathological origins.
Early effects were detected whether BLM was present or not, and
they were transient and fully reversible. Our observations support
the hypothesis that EPs provoked a vascular closure of vessels
afferent to the electropulsed area, as well as an immediate local
oedema. The local closure of arterial vascular supply of the pulsed
areas, that can explain, at least partly, the absence ofbleeding, prob-
ably involved the muscularis propria layer of arterioles causing a
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steady constriction of electropulsed vessels. Evidence for this is
furnished by (a) the dramatic reduction in the size of the spleens
after EP application, (b) the reduced diameter of mesenteric vessel
branches after EP delivery on the pancreas, (c) the absence offluo-
rescence of the treated area consecutive to the application of EPs
and fluorescein injection. However, venous occlusion was probably
also present and could also explain the absence of bleeding after
several EP runs. This venous occlusion would depend on other EP
effects at the sinusoidal or capillary levels, such as an enhanced
vascular permeability that could cause the local congestion and
oedema. The presence offibrin deposits between the vascular layers
as well as the perivascular oedema observed on mesenteric vessels
confirm the possibility ofan enhanced vascular permeability.
The late vascular effects observed in this study should be recog-
nized as specific damage due to the presence of BLM as great
differences were noticed between tissues submitted to ECT or to
EPs alone. We hypothesize that this was the consequence of BLM
electroloading into the endothelial cells constituting the electro-
pulsed volume. Indeed, the endothelial cells are submitted to the
highest BLM exposure after the BLM i.v. administration, and they
can be permeabilized in the same way (and in fact even more
easily because of the geometry of the current lines following the
vascular axes that have the highest conductivities) as all other cells
in tissues, either healthy, stromal or tumour cells. This hypothesis
is supported by the intense vascular lesions revealed by our
extensive histological analysis of the ECT-treated tumours.
Furthermore, the large infarction areas observed 9 days after ECT
demonstrate a vascular toxicity, only detectable when BLM was
present. Thus, beside the massive killing of the tumour cells
directly caused by BLM cytotoxicity on tumour cells, ECT-
induced vascular effects appear to constitute an additional anti-
tumour mechanism ofthis therapy. However, we are not yet able to
quantify the role of the vascular effects in the overall anti-tumour
response, but it will possibly provide an additional target for
specific modulations to improve the anti-tumour effect ofECT.
Immunological aspects
As immunological markers of the VX2 tumours are not well
known, we did not perform detailed analyses ofthe immunological
responses in the treated rabbits. However, based on our previous
experience using an IL-2-based immunotherapy that gave systemic
anti-tumour effects after ECT in murine models (Mir et al, 1995b;
S Orlowski et al, manuscript in preparation), this immunotherapy
was combined with ECT in rabbits to investigate the potential
systemic effects of that combination. The usual protocols in mice
comprised three injections of CHO(IL-2) cells in the peritumoral
oedema at days 1, 2 and 3 or 5 after ECT. As in our liver tumour
model, tumours were accessible only after a subxyphoid incision
in anaesthetized rabbits, we performed one single intratumoral
injection within the 10 min after the ECT.
The intratumoral injection of CHO(IL-2) cells in the absence of
ECT led to an increase in the number of metastases at necropsy in
four out offive rabbits. This could be due (a) to a possible transient
increase in the intratumoral fluid pressure resulting from the intra-
tumoral injection of 200-300 pl of medium with CHO(IL-2) cells
and (b) to the existence of the hole created by the needle used to
inject the cells. Thus, a possible release of tumour cells could
explain the observed increase in metastases generation. However, in
the fifth rabbit of this group, the number of metastases was largely
decreased and the non-implanted liver lobes and the lungs were
completely protected from metastatic spreading. This shows the
potentialities ofthe administered immunotherapy, even if, alone, itis
insufficient to control the growth ofthe transplanted tumour.
After ECT, in spite of the fact that the immunotherapy protocol
consisted of only one injection, the anti-tumour effects of the
combined therapy were clearly superior to those of the ECT alone
(Table 2), in particular when considering the control of the
metastatic dissemination. Thus, as previously observed in mice
(Mir et al, 1995b), this IL-2-based immunotherapy administered
after the ECT gives better local anti-tumour effects than the ECT
alone, as well as distant systemic anti-tumour effects. Our previous
results in mice showed that after the combination of ECT and
xenogeneic IL-2-secreting cells, distant anti-tumour effects are
achieved by the generation of CD4+ and CD8+ cells (Mir et al,
1995b). A similar situation in rabbits could explain the observed
reduction in the number ofmetastases. Indeed, the massive tumour
cell lysis due to the ECT, acting both as a 'tumour mass debulking
agent' and as an 'immune system activating factor', could allow
potential tumour-specific antigen release in the inflammatory
response context revealed by the peritumoral oedema, i.e. in the
presence of antigen-presenting cells such as macrophages. In this
context, the prolonged presence of the IL-2, continously released
by the injected cells, could result in the reconstitution of an effec-
tive immune response able to override tumour anergy mechanisms.
In conclusion, ECT, in the absence of concomitant immuno-
therapy, is a local anti-tumour treatment. Its efficacy involves the
direct cytotoxic effect ofthe bleomycin entering the electroperme-
abilized cells, as well as vascular and local immune effects. The
combination of an IL-2-based local immunotherapy can turn ECT
into a systemic anti-tumour treatment. Altogether, our results
provide evidence that ECT is applicable for the treatment of large
and ofdeep tumours.
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